Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography.
Histamine H1-receptor (H1R) antagonists, or antihistamines, often induce sedative side effects when used for the treatment of allergic disorders. This study compared the sedative profiles of the second-generation antihistamines, fexofenadine and cetirizine, using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of histamine H1-receptor occupancy (H1RO) in the brain. Subjective sleepiness and psychomotor performance were measured in 20 healthy Japanese volunteers at baseline and 90 min after administration of fexofenadine 120 mg or cetirizine 20 mg in a double-blind, placebo-controlled crossover study. Hydroxyzine 30 mg was included as a positive control. H1RO was measured using positron emission tomography (PET) with (11)C-doxepin in 12 of the 20 subjects, and a further 11 volunteers were recruited to act as controls. In psychomotor tests, fexofenadine was not significantly different from placebo and significantly less impairing than cetirizine on some tasks, as well as significantly less impairing than hydroxyzine on all tasks. For subjective sleepiness, fexofenadine was not significantly different from placebo, whereas cetirizine showed a trend toward increased sleepiness compared with fexofenadine and placebo. H1RO was negligible with fexofenadine (-0.1%) but moderately high with cetirizine (26.0%). In conclusion, fexofenadine 120 mg is distinguishable from cetirizine 20 mg, as assessed by H1RO and psychomotor testing.
Tashiro
Manabu
M
Department of Pharmacology, Tohoku University School of Medicine, 2-1 Seiryo-cho, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
Sakurada
Yumiko
Y
Iwabuchi
Kentaro
K
Mochizuki
Hideki
H
Kato
Motohisa
M
Aoki
Mariko
M
Funaki
Yoshihito
Y
Itoh
Masatoshi
M
Iwata
Ren
R
Wong
Dean F
DF
Yanai
Kazuhiko
K
D000328:Adult; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002250:Carbon Radioisotopes; D017332:Cetirizine / Q000493:pharmacokinetics / Q000494:pharmacology*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004316:Doxepin; D006634:Histamine H1 Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology*; D039563:Histamine H1 Antagonists, Non-Sedating / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D008297:Male; D049268:Positron-Emission Tomography; D017410:Practice Guidelines as Topic; D011597:Psychomotor Performance / Q000187:drug effects; D011969:Receptors, Histamine H1 / Q000378:metabolism*; D012894:Sleep Stages / Q000187:drug effects; D016593:Terfenadine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology*
D002250:Carbon Radioisotopes; D006634:Histamine H1 Antagonists; D039563:Histamine H1 Antagonists, Non-Sedating; D011969:Receptors, Histamine H1; D004316:Doxepin; D016593:Terfenadine; C093230:fexofenadine; D017332:Cetirizine